Conmed Corp insider trading
Every open-market purchase and sale by Conmed Corp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Conmed Corp’s insiders pay?
From February 9, 2010 to September 15, 2025, 36 insiders reported 25 open-market purchases and 204 sales not made under a pre-set plan in Conmed Corp. Twelve months after each purchase was reported, the shares were −4.5% against the S&P 500 on average (median −10.2%), over 25 purchases with a full year of prices; 28% beat the index. After sales, the shares moved −5.0% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 16, 2013 into $46,196 by November 2, 2026, +12.3% a year. It held shares 58% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $36,808 (+10.4% a year), and held throughout $57,029 (+14.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Jonas Daniel S | Special Counsel & Corp Secy | 0 | — | — | 26 | −2.2% (26) | May 2, 2023 |
| Peters Stanley W III | President AS and AET | 0 | — | — | 18 | −23.7% (18) | June 17, 2024 |
| Hartman Curt R | President, CEO and Chair | 4 | +10.9% (4) | 50% | 9 | −20.9% (9) | June 16, 2023 |
| Berge Terence M | VP-Corporate Controller | 0 | — | — | 11 | −7.0% (11) | May 2, 2023 |
| Corasanti Joseph J | Former President & CEO | 0 | — | — | 11 | +5.4% (11) | July 31, 2014 |
| Abraham William | EVP-Business Development | 0 | — | — | 10 | +18.3% (10) | September 4, 2014 |
| Cohen Heather L | EVP CORP HR | 2 | +43.2% (2) | 100% | 8 | +6.7% (8) | May 6, 2021 |
| Farkas Charles | Director | 8 | −9.9% (8) | 13% | 2 | −48.1% (2) | September 15, 2025 |
| Daniels Bruce | Director | 0 | — | — | 9 | +10.0% (9) | July 31, 2014 |
| Kennedy John Jed | Group Executive Vice President | 0 | — | — | 9 | −16.3% (9) | March 7, 2022 |
| Pomilio Luke A | EVP, Finance & CFO | 0 | — | — | 9 | +20.6% (9) | March 5, 2018 |
| Shagory Peter K | EVP, STRAT & CORP DEVT | 0 | — | — | 9 | −8.7% (9) | May 2, 2023 |
| Golden Jo Ann | Director | 0 | — | — | 8 | +10.6% (8) | May 11, 2018 |
| Schwartz Stuart J | Director | 0 | — | — | 8 | +9.2% (8) | October 30, 2013 |
| Pelletier Johonna Marie | Treasurer and VP, Tax | 0 | — | — | 7 | −13.7% (7) | May 2, 2023 |
| Corasanti Eugene R | Director | 0 | — | — | 6 | −0.5% (6) | November 22, 2013 |
| Darling Joseph G | EVP, Commercial Operations | 0 | — | — | 6 | +4.9% (6) | November 20, 2014 |
| Kuyper Dirk | Director | 1 | +1.7% (1) | 100% | 4 | −6.5% (4) | August 6, 2019 |
| Beyer Pat | Chief Operating Officer | 2 | −27.7% (2) | 0% | 2 | −32.9% (2) | May 2, 2024 |
| Concannon Brian | Director | 0 | — | — | 4 | −34.9% (4) | June 8, 2023 |
| Garner Todd W | Executive Vice President & CFO | 0 | — | — | 4 | −33.0% (4) | August 8, 2025 |
| Mandia Stephen | Director | 0 | — | — | 4 | −17.2% (4) | May 29, 2015 |
| Shallish Robert D Jr | EVP, Finance, CFO | 0 | — | — | 4 | +10.2% (4) | October 30, 2014 |
| Tryniski Mark E | Director | 1 | +37.6% (1) | 100% | 3 | −9.4% (3) | November 8, 2021 |
| Workman John L | Director | 3 | −17.6% (3) | 0% | 0 | — | March 2, 2020 |
| Bronson David M. | Director | 2 | −17.0% (2) | 0% | 0 | — | May 14, 2024 |
| Folkert Nathan | VP GM Orthopedics | 0 | — | — | 2 | −3.9% (2) | May 29, 2019 |
| Johnson David Allen | VP - Global Operations | 0 | — | — | 2 | −8.1% (2) | February 9, 2010 |
| Jones Gregory Renard | EVP-Corporate QA/RA | 0 | — | — | 2 | −16.4% (2) | August 13, 2015 |
| Lande Jerome J. | Director | 0 | — | — | 2 | −5.3% (2) | May 17, 2022 |
| Schwarzentraub Barbara J | Director | 1 | −31.8% (1) | 0% | 1 | −20.5% (1) | May 10, 2024 |
| Aronson Martha Goldberg | Director | 1 | −27.9% (1) | 0% | 0 | — | May 8, 2024 |
| Ferrell John D. | Executive Vice President - HR | 0 | — | — | 1 | −69.9% (1) | June 9, 2023 |
| Glaze Richard | Chief Information Officer | 0 | — | — | 1 | −43.1% (1) | February 13, 2025 |
| Ruiz-Caban Wilfredo | EVP QA, RA and Operations | 0 | — | — | 1 | +37.6% (1) | June 8, 2020 |
| Snyder Mark D | EVP Mfg. Ops & Business System | 0 | — | — | 1 | −19.5% (1) | March 7, 2016 |
When several insiders traded Conmed Corp
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Conmed Corp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 5 buying crowds with six months of prices, it averaged −9.5% against the index. After 12 selling crowds, +4.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 31, 2024 | 4 buying | −11.2% | −17.6% | −39.6% |
| May 31, 2023 | 7 selling | −14.7% | −21.7% | −64.5% |
| March 31, 2022 | 5 selling | −19.4% | −25.6% | −22.9% |
| August 31, 2020 | 3 selling | +14.3% | +32.6% | +22.1% |
| February 28, 2020 | 3 selling | −25.5% | −26.4% | −3.2% |
| May 31, 2019 | 5 selling | +19.3% | +25.8% | −20.6% |
| September 28, 2018 | 3 selling | −5.2% | +5.7% | +16.4% |
| March 29, 2018 | 3 selling | +12.4% | +14.8% | +21.2% |
| March 31, 2017 | 4 buying | +12.1% | +11.4% | +29.0% |
| December 31, 2015 | 2 buying | −4.3% | +7.4% | −9.8% |
| July 31, 2015 | 3 buying | −27.6% | −26.5% | −33.2% |
| May 29, 2015 | 2 buying | +1.3% | −22.0% | −29.3% |